Anti-IL-4/-13 based therapy in Asthma

Research output: Contribution to journalLiterature review

23 Citations (Scopus)

Abstract

It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of IL-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were for the most part disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review is an update of the evidence demonstrating the effectiveness or otherwise of the targeting of the TH2 cytokines IL-4 and IL-13 with biologics in patients with asthma.
Original languageEnglish
Pages (from-to)349-352
Number of pages4
JournalExpert Opinion on Emerging Drugs
Volume20
Issue number3
Early online date28 May 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Interleukin-13
Interleukin-4
Asthma
Biological Products
Therapeutics
Cytokines
Biological Therapy
Interleukin-5
Animal Models
Biomarkers
Clinical Trials
Inflammation
Phenotype
Lung
Population

Keywords

  • asthma
  • discriminatory biomarkers
  • IL-13
  • IL-4

Cite this

Anti-IL-4/-13 based therapy in Asthma. / Walsh, Garry M.

In: Expert Opinion on Emerging Drugs, Vol. 20, No. 3, 2015, p. 349-352.

Research output: Contribution to journalLiterature review

@article{1619321dcf0941c889c598784c0eda01,
title = "Anti-IL-4/-13 based therapy in Asthma",
abstract = "It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of IL-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were for the most part disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review is an update of the evidence demonstrating the effectiveness or otherwise of the targeting of the TH2 cytokines IL-4 and IL-13 with biologics in patients with asthma.",
keywords = "asthma, discriminatory biomarkers, IL-13, IL-4",
author = "Walsh, {Garry M}",
year = "2015",
doi = "10.1517/14728214.2015.1050377",
language = "English",
volume = "20",
pages = "349--352",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Anti-IL-4/-13 based therapy in Asthma

AU - Walsh, Garry M

PY - 2015

Y1 - 2015

N2 - It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of IL-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were for the most part disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review is an update of the evidence demonstrating the effectiveness or otherwise of the targeting of the TH2 cytokines IL-4 and IL-13 with biologics in patients with asthma.

AB - It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of IL-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were for the most part disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review is an update of the evidence demonstrating the effectiveness or otherwise of the targeting of the TH2 cytokines IL-4 and IL-13 with biologics in patients with asthma.

KW - asthma

KW - discriminatory biomarkers

KW - IL-13

KW - IL-4

U2 - 10.1517/14728214.2015.1050377

DO - 10.1517/14728214.2015.1050377

M3 - Literature review

VL - 20

SP - 349

EP - 352

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -